Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer

To compare the pathological effect between 2 cycles and 4 cycles of Capox regimen as neoadjuvant chemotherapy for low/ intermediate risk stage II/III rectal cancer.

NCT Number	NCT04922853
Lead Sponsor	West China Hospital Collaborators: The Third People's Hospital of Chengdu, Chengdu Fifth People's Hospital, Peking Union Medical College, Peking University Cancer Hospital & Institute, Sun Yat-Sen University Cancer Center, Second Affiliated Hospital, Zhejiang University, School of Medicine, Yunnan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Affiliated Hospital Of Guizhou Medical University, Sichuan Provincial People's Hospital, Nanchong Central Hospital, Dazhou Central Hospital, Leshan People's Hospital, GeneCast Biotechnology Co., Ltd.
Conditions	Rectal Cancer, Neoadjuvant Chemotherapy
Enrollment	554 participants
Start Date	2021-08-26
Primary Completion	2024-10-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-11